

Dakai Liu and Elazar Rabbani

Serial No. 09/046,840

Filed: March 24, 1998

Page 3 [Amendment In Connection With Submission Of Replacement
Sequence Listing] – March 18, 2008

REMARKS

By this Amendment, Applicants, through their attorney, are directing pursuant to 37 C.F.R. §1.82(e) the entry into the specification for this application (Serial No. 09/046,840, filed on March 24, 1998) the Replacement Sequence Listing, including the compliant computer readable form (CRF) thereof.

No fee is believed due in connection with this Amendment. In the event that any fee or fees are due, however, The Patent and Trademark Office is hereby authorized to charge the amount of any such fee(s) to Deposit Account No. 05-1135, and to credit any overpayment thereto.

Applicants respectfully request favorable action on their application. Should it be deemed helpful or necessary, the Examiner is respectfully invited to telephone the undersigned at (212) 583-0100 to discuss the subject application.

Respectfully submitted,



Ronald C. Fedus
Registration No. 32,567
Attorney for Applicants

ENZO THERAPEUTICS, INC.
c/o Enzo Biochem, Inc.
527 Madison Avenue, 9th Floor
New York, New York 10017
Tel.: (212) 583-0100
Fax.: (212) 583-0150